Statin use and risk of atrial fibrillation or flutter: A population-based case-control study

American Journal of Therapeutics

Volumn 22, Issue 3, 2015, Pages 186-194

  Veronese, Giacomo ^a   Montomoli, Jonathan ^a   Schmidt, Morten ^a   Horváth Puhó, Erzsébet ^a   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

atrial fibrillation; epidemiology; prevention; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GROUPS BY AGE; HEART ATRIUM FLUTTER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; ATRIAL FLUTTER; CASE CONTROL STUDY; RISK;

AGED; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RISK;

EID: 84929511055     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31827ab488     Document Type: Article

References (38)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with sim-vastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
3. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
4. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.
5. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
6. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271: 840-844.
7. Chien KL, Su TC, Hsu HC, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010;139:173-180.
8. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92:17-40, ix.
9. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.
10. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5:30-41.
11. Hodgkinson JA, Taylor CJ, Hobbs FD. Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study. Br J Gen Pract. 2011;61:e353-e361.
12. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308-328.
13. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13:610-625.
14. Patel AA, White CM, Shah SA, et al. The relationship between statin use and atrial fibrillation. Curr Med Res Opin. 2007;23:1177-1185.
15. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-Analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342:d1250.
16. Liu T, Li L, Korantzopoulos P, et al. Statin use and development of atrial fibrillation: a systematic review and meta-Analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126:160-170.
17. Xu Q, Guan YQ, Zhang D, et al. The effects of statin on atrial fibrillation: a meta-Analysis of published data from randomized controlled trials. Curr Med Res Opin. 2011; 27:1771-1779.
18. Wang Z, Zhang Y, Gao M, et al. Statin therapy for the prevention of atrial fibrillation: a meta-Analysis of randomized controlled trials. Pharmacotherapy. 2011;31:1051-1062.
19. Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-Analysis of randomized controlled trials. Br J Clin Pharmacol. 2012;74: 744-756.
20. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273-279.
21. Pedersen CB. The Danish Civil Registration system. Scand J Public Health. 2011;39:22-25.
22. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
23. Waldo AL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res. 2002;54:217-229.
24. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51:779-786.
25. Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011; 343:d3450.
26. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158: 915-920.
28. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98: 476-484.
29. van der Hooft CS, Heeringa J, van Herpen G, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44: 2117-2124.
30. Christiansen CF, Christensen S, Mehnert F, et al. Glu-cocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169:1677-1683.
31. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med. 2004; 164:1993-1998.
32. Mosbech J, Jorgensen J, Madsen M, et al. The national patient registry. Evaluation of data quality [Article in Danish]. Ugeskr Laeger. 1995;157:3741-3745.
33. Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
34. Johannesdottir SA, Maegbaek ML, Hansen JG, et al. Correspondence between general practitioner-reported medication use and timing of prescription dispensation. Clin Epidemiol. 2012;4:13-18.
35. Thomsen RW, Nielsen RB, Norgaard M, et al. Lifestyle profile among statin users. Pharmacoepidemiol Drug Saf. 2011;20:S111-S112.
36. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123:2094-2100.
37. Akahane T, Mizushige K, Nishio H, et al. Atrial fibrillation induced by simvastatin treatment in a 61-year-old man. Heart Vessels. 2003;18:157-159.
38. Sicouri S, Gianetti B, Zygmunt AC, et al. Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol. 2011;57:986-993.